Dr. Jurcic on the Next Steps for Radioimmunotherapy
Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses the next steps for research into radioimmunotherapy.
Radioimmunotherapy holds promise in multiple applications, Jurcic says. Preclinically, this therapy is being applied as conditioning for stem cell transplant. Encouraging results have been seen with beta-emitters.
Radioimmunotherapy may also be beneficial when using alpha particles to reduce toxicity yet gain an anti-tumor effect. In general, increasing the delivery of isotope to tumor cells but avoid toxicity has shown promise in preclinical studies.